Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…Abstract Number: 1696 • 2014 ACR/ARHP Annual Meeting
Left Atrial Area Measurement Is Useful for Evaluating Left Ventricular Diastolic Dysfunction Coexisting with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a crucial organ involvement affecting survival of patients with connective tissue disease (CTDs), such as systemic sclerosis (SSc), systemic…Abstract Number: 1692 • 2014 ACR/ARHP Annual Meeting
The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement
Background/Purpose: Severe nailfold videocapillaroscopy (NVC) patterns in patients with systemic sclerosis (SSc) are associated with a high risk of organ involvement. SSc-specific autoantibodies seem to…Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…Abstract Number: 724 • 2014 ACR/ARHP Annual Meeting
Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and the leading cause of morbidity and mortality. Serial pulmonary function tests…Abstract Number: 1814 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study
Background/Purpose: Data on the risk of pulmonary embolism (PE) and deep venous thrombosis (DVT) in patients with systemic sclerosis (SSc) is lacking. To fill this…Abstract Number: 1775 • 2013 ACR/ARHP Annual Meeting
Use Of “Computer-Aided Lung Informatics For Pathology Evaluation and Rating” Software In High-Resolution Computed Tomography In Patients With Idiopathic Inflammatory Myopathy and Interstitial Lung Disease
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are associated with interstitial lung disease (ILD), characterized by parenchymal abnormalities on high-resolution computed tomography (HRCT). We determined the…Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…Abstract Number: 738 • 2013 ACR/ARHP Annual Meeting
Pulmonary Fibrosis In ANCA-Associated Vasculitis
Background/Purpose: The association of pulmonary fibrosis (PF) with anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), especially microscopic polyangiitis (MPA), is rare but related to poor…Abstract Number: 2707 • 2013 ACR/ARHP Annual Meeting
Downregulation Of KLF5 and Fli1 Cooperatively Contribute To Distinct Manifestations Of Systemic Sclerosis In Vitro and In Vivo
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although the…Abstract Number: 695 • 2013 ACR/ARHP Annual Meeting
Combined Pulmonary Fibrosis and Emphysema (CPFE) In Systemic Sclerosis
Combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis Background/Purpose: Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome, in which centrilobular and/or…Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting
A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms
Background/Purpose: In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting
Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…Abstract Number: 2610 • 2013 ACR/ARHP Annual Meeting
A New Pathogenic Role Of BAFF As a Critical Mediator Of Skin and Lung Fibrosis In Experimental Bleomycin-Induced Pulmonary Fibrosis, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis
Background/Purpose: Interstitial pneumonitis and lung fibrosis are frequent systemic complications of inflammatory arthritides, including systemic sclerosis (SSc), rheumatoid arthritis, or primary Sjögren’s syndrome. B lymphocytes…Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »